{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:46:36Z","timestamp":1790635596065,"version":"4.1.0"},"reference-count":14,"publisher":"Scientific Scholar","content-domain":{"domain":["jpalliativecare.com"],"crossmark-restriction":true},"short-container-title":["IJPC"],"abstract":"<jats:p>Opiates are generally used to relieve dyspnoea in advanced diseases such as cancer and lung diseases. However, little is known regarding the safety and efficacy of morphine for refractory dyspnoea in coronavirus disease 2019 (COVID-19) patients. We retrospectively reviewed records of 18 COVID-19-positive patients who were administered morphine for refractory dyspnoea during hospitalisation between May 2021 and June 2021. Details of morphine usage, vital signs, an 11-point dyspnoea numeric rating scale (DNRS) and adverse events at baseline, 24 h and 72 h after the start of treatment were abstracted from records. The final clinical outcome in terms of death or discharge was noted. All patients had severe refractory dyspnoea (DNRS score \u22657) at the time of administration of morphine and had not been relieved from standard care for the past 3 days. In the results, the mean (standard deviation [SD]) age was 47.1 (12) years, male was 13 (72.20%) patients and modified Medical Research Council Grade 4 was present in all 18 patients. The mean (SD) 1<jats:sup>st<\/jats:sup> day dose of morphine was 7.03 (1.53) mg and the mean (SD) duration of morphine use was 5.22 (3.00) days. Significant decreases in DNRS, respiratory rate and oxygen saturation were observed 24 h and 72 h after the start of morphine administration. Meanwhile, blood pressure and heart rate were not significantly altered after treatment. The finding of this single-centre retrospective study indicates that morphine may be considered for use in the management of refractory dyspnoea among COVID-19 patients.<\/jats:p>","DOI":"10.25259\/ijpc_112_2022","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T12:04:45Z","timestamp":1661429085000},"page":"443-446","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness of Morphine in Managing Refractory Dyspnoea in Patients with Coronavirus Disease (COVID-19)"],"prefix":"10.25259","volume":"28","author":[{"given":"Prashant","family":"Sirohiya","sequence":"first","affiliation":[{"name":"Department of Oncoanaesthesia and Palliative Medicine, National Cancer Institute (Jhajjar), All India Institute of Medical Sciences, New Delhi, India,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khushboo","family":"Pandey","sequence":"additional","affiliation":[{"name":"Department of Oncoanaesthesia and Palliative Medicine, National Cancer Institute (Jhajjar), All India Institute of Medical Sciences, New Delhi, India,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari Krishna Raju","family":"Sagiraju","sequence":"additional","affiliation":[{"name":"Department of Preventive Oncology, All India Institute of Medical Sciences, New Delhi, India,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma","family":"Bhatnagar","sequence":"additional","affiliation":[{"name":"Department of Oncoanaesthesia and Palliative Medicine, Dr. B.R. Ambedkar Institute Rotary Cancer Hospital and National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"key":"10.25259\/IJPC_112_2022\/ref-1","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2016.0834","article-title":"The differential diagnosis of dyspnea","author":"Berliner","year":"2016","journal-title":"Dtsch Aerzteblatt Online"},{"key":"10.25259\/IJPC_112_2022\/ref-2","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1183\/09031936.00092613","article-title":"Dyspnoea: A multidimensional and multidisciplinary approach","volume":"43","author":"Laviolette","year":"2014","journal-title":"Eur Respir J"},{"key":"10.25259\/IJPC_112_2022\/ref-3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1164\/rccm.201111-2042ST","article-title":"An official American thoracic society statement: Update on the mechanisms, assessment, and management of dyspnea","volume":"185","author":"Parshall","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.25259\/IJPC_112_2022\/ref-4","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.25259\/IJPC_112_2022\/ref-5","doi-asserted-by":"publisher","first-page":"2003448","DOI":"10.1183\/13993003.03448-2020","article-title":"Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19","volume":"57","author":"Lerum","year":"2021","journal-title":"Eur Respir J"},{"key":"10.25259\/IJPC_112_2022\/ref-6","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1159\/000509104","article-title":"Position paper for the state-of-the-art application of respiratory support in patients with COVID-19","volume":"99","author":"Pfeifer","year":"2020","journal-title":"Respiration"},{"key":"10.25259\/IJPC_112_2022\/ref-7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1136\/thoraxjnl-2019-213681","article-title":"Regular, sustained-release morphine for chronic breathlessness: A multicentre, double-blind, randomised, placebo-controlled trial","volume":"75","author":"Currow","year":"2020","journal-title":"Thorax"},{"key":"10.25259\/IJPC_112_2022\/ref-8","doi-asserted-by":"publisher","first-page":"m1461","DOI":"10.1136\/bmj.m1461","article-title":"Managing COVID-19 symptoms (including at the end of life) in the community: Summary of NICE guidelines","volume":"369","author":"National Institute for Health and Care Excellence (NICE) in collaboration with NHS England and NHS Improvement","year":"2020","journal-title":"BMJ"},{"key":"10.25259\/IJPC_112_2022\/ref-9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.accpm.2014.09.001","article-title":"Assessment of dyspnoea in the emergency department by numeric and visual scales: A pilot study","volume":"34","author":"Placido","year":"2015","journal-title":"Anaesth Crit Care Pain Med"},{"key":"10.25259\/IJPC_112_2022\/ref-10","doi-asserted-by":"publisher","first-page":"084","DOI":"10.1183\/23120541.00084-2017","article-title":"mMRC dyspnoea scale indicates impaired quality of life and increased pain in patients with idiopathic pulmonary fibrosis","volume":"3","author":"Rajala","year":"2017","journal-title":"ERJ Open Res"},{"key":"10.25259\/IJPC_112_2022\/ref-11","first-page":"13062","article-title":"Consideration of immunomodulatory actions of morphine in COVID-19-short report","volume":"24","author":"Hudzik","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.25259\/IJPC_112_2022\/ref-12","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1200\/JCO.20.03465","article-title":"Management of dyspnea in advanced cancer: ASCO guideline","volume":"39","author":"Hui","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.25259\/IJPC_112_2022\/ref-13","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1164\/ajrccm.157.6.9711061","article-title":"The effect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease","volume":"157","author":"Poole","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.25259\/IJPC_112_2022\/ref-14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1586\/ers.13.5","article-title":"Opioids for refractory dyspnea","volume":"7","author":"Mahler","year":"2013","journal-title":"Expert Rev Respir Med"}],"container-title":["Indian Journal of Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jpalliativecare.com\/effectiveness-of-morphine-in-managing-refractory-dyspnoea-in-patients-with-coronavirus-disease-covid-19\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jpalliativecare.com\/effectiveness-of-morphine-in-managing-refractory-dyspnoea-in-patients-with-coronavirus-disease-covid-19\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T07:23:20Z","timestamp":1679297000000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpalliativecare.com\/effectiveness-of-morphine-in-managing-refractory-dyspnoea-in-patients-with-coronavirus-disease-covid-19\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":14,"alternative-id":["10.25259\/IJPC_112_2022"],"URL":"https:\/\/doi.org\/10.25259\/ijpc_112_2022","relation":{},"ISSN":["1998-3735","0973-1075"],"issn-type":[{"value":"1998-3735","type":"electronic"},{"value":"0973-1075","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,25]]},"article-number":"443"}}